Eintrag weiter verarbeiten
Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential
Gespeichert in:
| Zeitschriftentitel: | Antimicrobial Agents and Chemotherapy |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Antimicrobial Agents and Chemotherapy, 48, 2004, 8, S. 3086-3092 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society for Microbiology
|
| Schlagwörter: |
| author_facet |
Mushtaq, Shazad Ge, Yigong Livermore, David M. Mushtaq, Shazad Ge, Yigong Livermore, David M. |
|---|---|
| author |
Mushtaq, Shazad Ge, Yigong Livermore, David M. |
| spellingShingle |
Mushtaq, Shazad Ge, Yigong Livermore, David M. Antimicrobial Agents and Chemotherapy Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential Infectious Diseases Pharmacology (medical) Pharmacology |
| author_sort |
mushtaq, shazad |
| spelling |
Mushtaq, Shazad Ge, Yigong Livermore, David M. 0066-4804 1098-6596 American Society for Microbiology Infectious Diseases Pharmacology (medical) Pharmacology http://dx.doi.org/10.1128/aac.48.8.3086-3092.2004 <jats:title>ABSTRACT</jats:title> <jats:p> Doripenem is a broad-spectrum parenteral carbapenem under clinical development in Japan and North America. Its activities against (i) <jats:italic>Pseudomonas aeruginosa</jats:italic> isolates with graded levels of intrinsic efflux-type resistance, (ii) mutants with various combinations of AmpC and OprD expression, (iii) PU21 transconjugants with class A and D β-lactamases, and (iv) <jats:italic>P. aeruginosa</jats:italic> isolates with metallo-β-lactamases were tested by the agar dilution method of the National Committee for Clinical Laboratory Standards. Selection of resistant <jats:italic>P. aeruginosa</jats:italic> mutants was investigated in single- and multistep procedures. Doripenem MICs for isolates without acquired resistance mostly were 0.12 to 0.5 μg/ml, whereas meropenem MICs were 0.25 to 0.5 μg/ml and imipenem MICs were 1 to 2 μg/ml. The MICs of doripenem, meropenem, ertapenem, and noncarbapenems for isolates with increased efflux-type resistance were elevated, whereas the MICs of imipenem were less affected. The MICs of doripenem were increased by the loss of OprD but not by derepression of AmpC; nevertheless, and as with other carbapenems, the impermeability-determined resistance caused by the loss of OprD corequired AmpC activity and was lost in OprD <jats:sup>−</jats:sup> mutants also lacking AmpC. The TEM, PSE, PER, and OXA enzymes did not significantly protect <jats:italic>P. aeruginosa</jats:italic> PU21 against the activity of doripenem, whereas MICs of ≥16 μg/ml were seen for clinical isolates with VIM and IMP metallo-β-lactamases. Resistant mutants seemed to be harder to select with doripenem than with other carbapenems (or noncarbapenems), and the fold increases in the MICs were smaller for the resistant mutants. Single-step doripenem mutants were mostly resistant only to carbapenems and had lost OprD; multistep mutants had broader resistance, implying the presence of additional mechanisms, putatively including up-regulated efflux. Most mutants selected with aminoglycosides and quinolones had little or no cross-resistance to carbapenems, including doripenem. </jats:p> Doripenem versus <i>Pseudomonas aeruginosa</i> In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential Antimicrobial Agents and Chemotherapy |
| doi_str_mv |
10.1128/aac.48.8.3086-3092.2004 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuNDguOC4zMDg2LTMwOTIuMjAwNA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuNDguOC4zMDg2LTMwOTIuMjAwNA |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
| imprint |
American Society for Microbiology, 2004 |
| imprint_str_mv |
American Society for Microbiology, 2004 |
| issn |
0066-4804 1098-6596 |
| issn_str_mv |
0066-4804 1098-6596 |
| language |
English |
| mega_collection |
American Society for Microbiology (CrossRef) |
| match_str |
mushtaq2004doripenemversuspseudomonasaeruginosainvitroactivityagainstcharacterizedisolatesmutantsandtransconjugantsandresistanceselectionpotential |
| publishDateSort |
2004 |
| publisher |
American Society for Microbiology |
| recordtype |
ai |
| record_format |
ai |
| series |
Antimicrobial Agents and Chemotherapy |
| source_id |
49 |
| title |
Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_unstemmed |
Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_full |
Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_fullStr |
Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_full_unstemmed |
Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_short |
Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_sort |
doripenem versus
<i>pseudomonas aeruginosa</i>
in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential |
| topic |
Infectious Diseases Pharmacology (medical) Pharmacology |
| url |
http://dx.doi.org/10.1128/aac.48.8.3086-3092.2004 |
| publishDate |
2004 |
| physical |
3086-3092 |
| description |
<jats:title>ABSTRACT</jats:title>
<jats:p>
Doripenem is a broad-spectrum parenteral carbapenem under clinical development in Japan and North America. Its activities against (i)
<jats:italic>Pseudomonas aeruginosa</jats:italic>
isolates with graded levels of intrinsic efflux-type resistance, (ii) mutants with various combinations of AmpC and OprD expression, (iii) PU21 transconjugants with class A and D β-lactamases, and (iv)
<jats:italic>P. aeruginosa</jats:italic>
isolates with metallo-β-lactamases were tested by the agar dilution method of the National Committee for Clinical Laboratory Standards. Selection of resistant
<jats:italic>P. aeruginosa</jats:italic>
mutants was investigated in single- and multistep procedures. Doripenem MICs for isolates without acquired resistance mostly were 0.12 to 0.5 μg/ml, whereas meropenem MICs were 0.25 to 0.5 μg/ml and imipenem MICs were 1 to 2 μg/ml. The MICs of doripenem, meropenem, ertapenem, and noncarbapenems for isolates with increased efflux-type resistance were elevated, whereas the MICs of imipenem were less affected. The MICs of doripenem were increased by the loss of OprD but not by derepression of AmpC; nevertheless, and as with other carbapenems, the impermeability-determined resistance caused by the loss of OprD corequired AmpC activity and was lost in OprD
<jats:sup>−</jats:sup>
mutants also lacking AmpC. The TEM, PSE, PER, and OXA enzymes did not significantly protect
<jats:italic>P. aeruginosa</jats:italic>
PU21 against the activity of doripenem, whereas MICs of ≥16 μg/ml were seen for clinical isolates with VIM and IMP metallo-β-lactamases. Resistant mutants seemed to be harder to select with doripenem than with other carbapenems (or noncarbapenems), and the fold increases in the MICs were smaller for the resistant mutants. Single-step doripenem mutants were mostly resistant only to carbapenems and had lost OprD; multistep mutants had broader resistance, implying the presence of additional mechanisms, putatively including up-regulated efflux. Most mutants selected with aminoglycosides and quinolones had little or no cross-resistance to carbapenems, including doripenem.
</jats:p> |
| container_issue |
8 |
| container_start_page |
3086 |
| container_title |
Antimicrobial Agents and Chemotherapy |
| container_volume |
48 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792338427605155845 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:31:44.371Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Doripenem+versus++++++++++++Pseudomonas+aeruginosa++++++++++++In+Vitro%3A+Activity+against+Characterized+Isolates%2C+Mutants%2C+and+Transconjugants+and+Resistance+Selection+Potential&rft.date=2004-08-01&genre=article&issn=1098-6596&volume=48&issue=8&spage=3086&epage=3092&pages=3086-3092&jtitle=Antimicrobial+Agents+and+Chemotherapy&atitle=Doripenem+versus%0A++++++++++++%3Ci%3EPseudomonas+aeruginosa%3C%2Fi%3E%0A++++++++++++In+Vitro%3A+Activity+against+Characterized+Isolates%2C+Mutants%2C+and+Transconjugants+and+Resistance+Selection+Potential&aulast=Livermore&aufirst=David+M.&rft_id=info%3Adoi%2F10.1128%2Faac.48.8.3086-3092.2004&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792338427605155845 |
| author | Mushtaq, Shazad, Ge, Yigong, Livermore, David M. |
| author_facet | Mushtaq, Shazad, Ge, Yigong, Livermore, David M., Mushtaq, Shazad, Ge, Yigong, Livermore, David M. |
| author_sort | mushtaq, shazad |
| container_issue | 8 |
| container_start_page | 3086 |
| container_title | Antimicrobial Agents and Chemotherapy |
| container_volume | 48 |
| description | <jats:title>ABSTRACT</jats:title> <jats:p> Doripenem is a broad-spectrum parenteral carbapenem under clinical development in Japan and North America. Its activities against (i) <jats:italic>Pseudomonas aeruginosa</jats:italic> isolates with graded levels of intrinsic efflux-type resistance, (ii) mutants with various combinations of AmpC and OprD expression, (iii) PU21 transconjugants with class A and D β-lactamases, and (iv) <jats:italic>P. aeruginosa</jats:italic> isolates with metallo-β-lactamases were tested by the agar dilution method of the National Committee for Clinical Laboratory Standards. Selection of resistant <jats:italic>P. aeruginosa</jats:italic> mutants was investigated in single- and multistep procedures. Doripenem MICs for isolates without acquired resistance mostly were 0.12 to 0.5 μg/ml, whereas meropenem MICs were 0.25 to 0.5 μg/ml and imipenem MICs were 1 to 2 μg/ml. The MICs of doripenem, meropenem, ertapenem, and noncarbapenems for isolates with increased efflux-type resistance were elevated, whereas the MICs of imipenem were less affected. The MICs of doripenem were increased by the loss of OprD but not by derepression of AmpC; nevertheless, and as with other carbapenems, the impermeability-determined resistance caused by the loss of OprD corequired AmpC activity and was lost in OprD <jats:sup>−</jats:sup> mutants also lacking AmpC. The TEM, PSE, PER, and OXA enzymes did not significantly protect <jats:italic>P. aeruginosa</jats:italic> PU21 against the activity of doripenem, whereas MICs of ≥16 μg/ml were seen for clinical isolates with VIM and IMP metallo-β-lactamases. Resistant mutants seemed to be harder to select with doripenem than with other carbapenems (or noncarbapenems), and the fold increases in the MICs were smaller for the resistant mutants. Single-step doripenem mutants were mostly resistant only to carbapenems and had lost OprD; multistep mutants had broader resistance, implying the presence of additional mechanisms, putatively including up-regulated efflux. Most mutants selected with aminoglycosides and quinolones had little or no cross-resistance to carbapenems, including doripenem. </jats:p> |
| doi_str_mv | 10.1128/aac.48.8.3086-3092.2004 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuNDguOC4zMDg2LTMwOTIuMjAwNA |
| imprint | American Society for Microbiology, 2004 |
| imprint_str_mv | American Society for Microbiology, 2004 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
| issn | 0066-4804, 1098-6596 |
| issn_str_mv | 0066-4804, 1098-6596 |
| language | English |
| last_indexed | 2024-03-01T15:31:44.371Z |
| match_str | mushtaq2004doripenemversuspseudomonasaeruginosainvitroactivityagainstcharacterizedisolatesmutantsandtransconjugantsandresistanceselectionpotential |
| mega_collection | American Society for Microbiology (CrossRef) |
| physical | 3086-3092 |
| publishDate | 2004 |
| publishDateSort | 2004 |
| publisher | American Society for Microbiology |
| record_format | ai |
| recordtype | ai |
| series | Antimicrobial Agents and Chemotherapy |
| source_id | 49 |
| spelling | Mushtaq, Shazad Ge, Yigong Livermore, David M. 0066-4804 1098-6596 American Society for Microbiology Infectious Diseases Pharmacology (medical) Pharmacology http://dx.doi.org/10.1128/aac.48.8.3086-3092.2004 <jats:title>ABSTRACT</jats:title> <jats:p> Doripenem is a broad-spectrum parenteral carbapenem under clinical development in Japan and North America. Its activities against (i) <jats:italic>Pseudomonas aeruginosa</jats:italic> isolates with graded levels of intrinsic efflux-type resistance, (ii) mutants with various combinations of AmpC and OprD expression, (iii) PU21 transconjugants with class A and D β-lactamases, and (iv) <jats:italic>P. aeruginosa</jats:italic> isolates with metallo-β-lactamases were tested by the agar dilution method of the National Committee for Clinical Laboratory Standards. Selection of resistant <jats:italic>P. aeruginosa</jats:italic> mutants was investigated in single- and multistep procedures. Doripenem MICs for isolates without acquired resistance mostly were 0.12 to 0.5 μg/ml, whereas meropenem MICs were 0.25 to 0.5 μg/ml and imipenem MICs were 1 to 2 μg/ml. The MICs of doripenem, meropenem, ertapenem, and noncarbapenems for isolates with increased efflux-type resistance were elevated, whereas the MICs of imipenem were less affected. The MICs of doripenem were increased by the loss of OprD but not by derepression of AmpC; nevertheless, and as with other carbapenems, the impermeability-determined resistance caused by the loss of OprD corequired AmpC activity and was lost in OprD <jats:sup>−</jats:sup> mutants also lacking AmpC. The TEM, PSE, PER, and OXA enzymes did not significantly protect <jats:italic>P. aeruginosa</jats:italic> PU21 against the activity of doripenem, whereas MICs of ≥16 μg/ml were seen for clinical isolates with VIM and IMP metallo-β-lactamases. Resistant mutants seemed to be harder to select with doripenem than with other carbapenems (or noncarbapenems), and the fold increases in the MICs were smaller for the resistant mutants. Single-step doripenem mutants were mostly resistant only to carbapenems and had lost OprD; multistep mutants had broader resistance, implying the presence of additional mechanisms, putatively including up-regulated efflux. Most mutants selected with aminoglycosides and quinolones had little or no cross-resistance to carbapenems, including doripenem. </jats:p> Doripenem versus <i>Pseudomonas aeruginosa</i> In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential Antimicrobial Agents and Chemotherapy |
| spellingShingle | Mushtaq, Shazad, Ge, Yigong, Livermore, David M., Antimicrobial Agents and Chemotherapy, Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential, Infectious Diseases, Pharmacology (medical), Pharmacology |
| title | Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_full | Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_fullStr | Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_full_unstemmed | Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_short | Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| title_sort | doripenem versus <i>pseudomonas aeruginosa</i> in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential |
| title_unstemmed | Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential |
| topic | Infectious Diseases, Pharmacology (medical), Pharmacology |
| url | http://dx.doi.org/10.1128/aac.48.8.3086-3092.2004 |